Search for: "J. M. v. C. M."
Results 21 - 40
of 3,858
Sort by Relevance
|
Sort by Date
10 May 2024, 6:00 am
Martoche, J.), entered April 14, 2023, in a proceeding pursuant to CPLR article 75. [read post]
10 May 2024, 6:00 am
Martoche, J.), entered April 14, 2023, in a proceeding pursuant to CPLR article 75. [read post]
9 May 2024, 7:00 am
., attorneys for amicus curiae New York State United Teachers, Christina M. [read post]
9 May 2024, 7:00 am
., attorneys for amicus curiae New York State United Teachers, Christina M. [read post]
8 May 2024, 6:00 am
Farra, Alyssa M. [read post]
8 May 2024, 6:00 am
Farra, Alyssa M. [read post]
6 May 2024, 5:10 pm
In Dobbs v. [read post]
1 May 2024, 11:04 am
Michael C. [read post]
30 Apr 2024, 3:12 pm
Sources, Characteristics and Identification E. coli is an archetypal commensal bacterial species that lives in mammalian intestines. [read post]
30 Apr 2024, 5:38 am
Bentley v. [read post]
29 Apr 2024, 8:09 am
"The geopolitical storm churned up by Edward J. [read post]
24 Apr 2024, 11:27 am
”[10] Fourth, the plaintiffs’ claims were before Chief Judge Nancy J. [read post]
23 Apr 2024, 10:56 am
C. 1229, which is now burned into my memory forever. [read post]
22 Apr 2024, 10:01 am
Donald J. [read post]
22 Apr 2024, 5:00 am
Trump (SDNY), YALE J. [read post]
15 Apr 2024, 6:00 pm
V. [read post]
13 Apr 2024, 3:33 pm
Prelude to Litigation Phenylpropanolamine (PPA) was a widely used direct α-adrenergic agonist used as a medication to control cold symptoms and to suppress appetite for weight loss.[1] In 1972, an over-the-counter (OTC) Advisory Review Panel considered the safety and efficacy of PPA-containing nasal decongestant medications, leading, in 1976, to a recommendation that the agency label these medications as “generally recognized as safe and effective. [read post]
9 Apr 2024, 3:52 pm
Schmid and V. [read post]
9 Apr 2024, 10:32 am
Tal como nas fórmulas do patético de Aby Warburg, não se distingue nelas criação e performance, original e cópia. [read post]
8 Apr 2024, 10:08 am
As a practical matter, the burden shifts to the party that wishes to challenge the relied upon facts and data to learn more about the cited studies to show that the facts and data are not sufficient under Rule 702(b), and that the testimony is not the product of reliable methods under Rule 702(c). [read post]